Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for

A Kuliopulos1, L Covic, S K Seeley

  • 1Molecular Cardiology Research Institute, Division of Hematology/Oncology, New England Medical Center, Boston, Massachusetts 02111, USA. akuliopu@opal.tufts.edu

Biochemistry
|April 9, 1999
PubMed

Insights

Anticoagulant proteases, like plasmin, can desensitize protease-activated receptor 1 (PAR1). This explains how plasmin and tissue plasminogen activator (t-PA) can both activate and deactivate platelets before thrombin exposure.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protease-activated receptors (PARs) are implicated in various physiological processes.
  • The PAR1 receptor, activated by thrombin, is crucial for platelet aggregation.
  • The dual role of plasmin/tissue plasminogen activator (t-PA) in platelet activation/deactivation remains unclear.

Purpose of the Study:

  • To investigate the desensitization mechanism of the PAR1 thrombin receptor by anticoagulant proteases.
  • To elucidate the role of plasmin and t-PA in PAR1 receptor modulation.
  • To explain the paradoxical activation and deactivation of platelets by plasmin/t-PA.

Main Methods:

  • Utilized a soluble N-terminal exodomain (TR78) of PAR1 as a model.
  • Compared cleavage rates and specificities of thrombin and anticoagulant proteases (plasmin) on TR78.
  • Assessed cleavage in full-length PAR1 expressed in yeast and COS7 fibroblasts.
  • Investigated the impact of mutations (R70/K76/K82 to A70/A76/A82) on plasmin cleavage and signaling.

Main Results:

  • Thrombin cleaves TR78 at R41-S42 (kcat=120 s-1, KM=16 microM).
  • Plasmin efficiently truncates TR78 at R70/K76/K82 sites (kcat=30 s-1, KM=18 microM), similar to thrombin's R41 cleavage.
  • Plasmin cleavage at R70/K76/K82 sites desensitizes thrombin-dependent Ca2+ signaling, while mutation eliminates this effect and confers plasmin agonist activity.
  • Plasmin does not desensitize SFLLRN-induced Ca2+ responses, suggesting ligand-binding sites are C-terminal to K82.

Conclusions:

  • Plasmin desensitizes the PAR1 receptor by cleaving specific sites on its exodomain.
  • This truncation mechanism explains the dual role of plasmin/t-PA in platelet function.
  • PAR1 can be effectively desensitized in vivo via C-terminal truncation by plasmin.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...